<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing guidelines when switching from one stimulant to another in the treatment of attention deficit hyperactivity disorder in children and adolescents*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing guidelines when switching from one stimulant to another in the treatment of attention deficit hyperactivity disorder in children and adolescents*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing guidelines when switching from one stimulant to another in the treatment of attention deficit hyperactivity disorder in children and adolescents*</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="25%"></colgroup> <colgroup span="2" width="12.5%"></colgroup> <tbody> <tr> <td class="subtitle1">Current medication and dose</td> <td class="subtitle1">New medication</td> <td class="subtitle1">Recommended starting dose</td> <td class="subtitle1" colspan="2">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Switching from one form of methylphenidate to another</td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 5 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release (Concerta)</td> <td>18 mg once daily in the morning</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 10 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release</td> <td>36 mg once daily in the morning</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 15 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release</td> <td>54 mg once daily in the morning</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 20 mg twice daily or three times daily</td> <td>Methylphenidate osmotic release</td> <td>72 mg once daily in the morning</td> <td colspan="2">Conversion dosage should not exceed 72 mg per day.</td> </tr> <tr> <td class="indent1">Methylphenidate IR</td> <td>Dexmethylphenidate (Focalin or Focalin XR)</td> <td>One-half the current total daily dose</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 5 mg three times per day</td> <td>Methylphenidate patch (Daytrana)</td> <td>10 mg (12.5 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2">Methylphenidate patch has greater systemic bioavailability than oral preparations. Patients changing from oral methylphenidate IR doses ≤20 mg per day should be started on the 10 mg patch. Allow at least 1 week before increasing to the next higher patch strength, if needed.</td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 7.5 mg three times per day</td> <td>Methylphenidate patch</td> <td>15 mg (18.75 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 10 mg three times per day</td> <td>Methylphenidate patch</td> <td>20 mg (25 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate IR<br/> 15 mg three times per day</td> <td>Methylphenidate patch</td> <td>30 mg (37.5 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate osmotic release<br/> 18 mg</td> <td>Methylphenidate patch</td> <td>10 mg (12.5 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate osmotic release<br/> 27 mg</td> <td>Methylphenidate patch</td> <td>15 mg (18.75 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate osmotic release<br/> 36 mg</td> <td>Methylphenidate patch</td> <td>20 mg (25 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1">Methylphenidate osmotic release<br/> 54 mg</td> <td>Methylphenidate patch</td> <td>30 mg (37.5 cm<sup>2</sup>) patch applied once daily</td> <td colspan="2"> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Switching to serdexmethylphenidate-dexmethylphenidate</td> </tr> <tr> <td class="indent1">Any stimulant<sup>¶</sup></td> <td>Serdexmethylphenidate-dexmethylphenidate (Azstarys)</td> <td>39.2/7.8 mg once daily in the morning</td> <td colspan="2">If switching from any other stimulant, including methylphenidate products, discontinue the treatment and titrate serdexmethylphenidate-dexmethylphenidate from the appropriate initial starting dose.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Switching to dextroamphetamine</td> </tr> <tr> <td class="indent1">Any stimulant<sup>¶</sup></td> <td>Dextroamphetamine or dextroamphetamine spansules</td> <td>5 mg once or twice per day</td> <td colspan="2">Daily dosage may be increased in increments of 5 mg at weekly intervals until optimal response is obtained (maximum daily dose 40 mg).</td> </tr> <tr> <td class="indent1">Any stimulant<sup>¶</sup></td> <td>Lisdexamfetamine (Vyvanse)</td> <td>30 mg once daily in the morning</td> <td colspan="2">Daily dosage may be increased in increments of 10 or 20 mg at approximately weekly intervals until optimal response is obtained (maximum daily dose 70 mg).</td> </tr> <tr> <td class="indent1">Any stimulant<sup>¶</sup><sup>Δ</sup></td> <td>Dextroamphetamine patch</td> <td>6 to 17 years: 4.5 mg per 9 hour patch applied once daily</td> <td colspan="2">Daily dosage may be increased in increments of 4.5 mg at approximately weekly intervals until optimal response is obtained (maximum daily dose 18 mg)</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Switching to dextroamphetamine-amphetamine</td> </tr> <tr> <td class="indent1" rowspan="2">Methylphenidate<sup>¶</sup><sup>◊</sup></td> <td rowspan="2">Dextroamphetamine-amphetamine IR</td> <td>6 to 12 years: 10 mg once daily in the morning</td> <td colspan="2">Daily dosage may be adjusted in increments of 5 or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 30 mg; may be divided in 2 doses).</td> </tr> <tr> <td>13 to 17 years: 10 mg once daily in the morning</td> <td colspan="2">Daily dosage may be adjusted in increments of 5 or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 40 mg; may be divided in 2 doses).</td> </tr> <tr> <td class="indent1">Dextroamphetamine-amphetamine (Adderall) IR</td> <td>Dextroamphetamine-amphetamine XR</td> <td>Same total daily dose</td> <td colspan="2"> </td> </tr> <tr> <td class="indent1" rowspan="2">Any stimulant other than dextroamphetamine-amphetamine IR<sup>¶</sup><sup>◊</sup></td> <td rowspan="2">Dextroamphetamine-amphetamine XR</td> <td>6 to 12 years: 10 mg once daily in the morning</td> <td colspan="2">Daily dosage may be adjusted in increments of 5 or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 30 mg/day).</td> </tr> <tr> <td>13 to 17 years: 10 mg once daily in the morning</td> <td colspan="2">Daily dosage may be increased to 20 mg/day after 1 week if symptoms are not adequately controlled.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Switching from one form of XR dextroamphetamine-amphetamine to another<sup>§</sup></td> </tr> <tr> <td class="indent1" rowspan="8">Dextroamphetamine-amphetamine XR (Adderall XR) capsule</td> <td rowspan="8"> <p>Amphetamine XR orally disintegrating tablet (Adzenys XR-ODT)</p> Amphetamine ER oral suspension (1.25 mg amphetamine base per mL, Adzenys ER)</td> <td rowspan="8">Each 5 mg of dextroamphetamine-amphetamine salts (Adderall XR) is equivalent to approximately 3.1 mg of amphetamine XR-ODT (Adzenys XR-ODT) or amphetamine ER oral suspension (Adzenys ER)</td> <td><strong>XR capsule (Adderall XR)</strong></td> <td><strong>Dose expressed as base: ODT-XR tablet and ER oral suspension (Adzenys XR-ODT, Adzenys ER)</strong></td> </tr> <tr> <td colspan="2">Approximate equivalence (taken once daily in the morning):</td> </tr> <tr> <td class="centered">5 mg</td> <td class="centered">3.1 mg</td> </tr> <tr> <td class="centered">10 mg</td> <td class="centered">6.3 mg</td> </tr> <tr> <td class="centered">15 mg</td> <td class="centered">9.4 mg</td> </tr> <tr> <td class="centered">20 mg</td> <td class="centered">12.5 mg</td> </tr> <tr> <td class="centered">25 mg</td> <td class="centered">15.7 mg</td> </tr> <tr> <td class="centered">30 mg</td> <td class="centered">18.8 mg</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IR: immediate release;
	XR: extended release;
	ODT: orally-disintegrating tablet;
	ER: extended release.</p>
<p>* Ultimate dose must be individualized based upon patient needs and response as children may respond differently to new medication.</p>
<p>¶ There are no reliable data to provide guidelines for switching between different classes of long-acting stimulants.</p>
<p>Δ Discontinue the previous stimulant and titrate the dextroamphetamine patch from the initial starting dose. Other amphetamine products have different amphetamine base compositions and pharmacokinetic profiles. They cannot be substituted on a milligram-per-milligram basis.</p>
<p>◊ When switching from methylphenidate to dextroamphetamine-amphetamine, the ultimate dose of dextroamphetamine-amphetamine is approximately one-half the current dose of methylphenidate (eg, 30 mg of methylphenidate is approximately equal to 15 mg of dextroamphetamine-amphetamine); however, for children who are currently receiving ≥20 mg per day of methylphenidate, we suggest converting to dextroamphetamine-amphetamine at a starting dose of 10 mg once per day and titrating the dose to the child's response (as described in the table).</p>
	
	§ Amphetamine XR-ODT (Adzenys XR-ODT) and amphetamine ER (Adzenys ER) strengths reflect milligrams of amphetamine base, whereas dextroamphetamine-amphetamine XR (Adderall XR) capsule strengths reflect milligrams of amphetamine salts. These cannot be substituted on a milligram-per-milligram basis. If switching from any other amphetamine product, discontinue the treatment and retitrate the new product from the appropriate initial starting dose.</div><div class="graphic_reference">Data from:
	<ol>
<li>US Food and Drug Administration approved product information. Available at: <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" target="_blank">www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a> (Accessed on March 29, 2022).</li>
<li>Arnold LE, Lindsay RL, López FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120:1100.</li>
</ol></div><div id="graphicVersion">Graphic 61007 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
